{
    "eid": "2-s2.0-85092331983",
    "title": "Dengue vaccine: Global development update",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "Dengue vaccine",
        "DNA vaccine",
        "Heterologous prime-boost",
        "Inactivated virus",
        "Live-attenuated virus",
        "Subunit vaccine"
    ],
    "authors": [
        "Eakachai Prompetchara",
        "Chutitorn Ketloy",
        "Stephen J. Thomas",
        "Kiat Ruxrungtham"
    ],
    "citedby-count": 34,
    "ref-count": 57,
    "ref-list": [
        "The global burden of dengue: an analysis from the Global Burden of Disease Study 2013",
        "Epidemiology of dengue: Past, present and future prospects",
        "Immunopathological mechanisms in dengue and dengue hemorrhagic fever",
        "Neutralization and Antibody-Dependent Enhancement of Dengue Viruses",
        "Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever",
        "Immune Response to Dengue Virus and Prospects for a Vaccine",
        "Wolbachia versus dengue",
        "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease",
        "The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries",
        "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial",
        "Efficacy of a tetravalent dengue vaccine in children in Latin America",
        "Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward",
        "Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; What makes this vaccine different from the Sanofi-Pasteur CYDTM vaccine?",
        "Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults",
        "The live attenuated dengue vaccine TV005 is well tolerated and highly immunogenic in flavivirus naive subjects 50-70 years of age",
        "Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever",
        "Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study",
        "Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: A randomized, placebo-controlled phase 2 study",
        "Differential Targeting of Viral Components by CD4+ versus CD8+ T Lymphocytes in Dengue Virus Infection",
        "Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial",
        "Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States",
        "Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial",
        "Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine",
        "Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines",
        "The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease",
        "New mouse model for dengue virus vaccine testing",
        "Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model",
        "New generation humanized mice for virus research: Comparative aspects and future prospects",
        "Humanized mice for immune system investigation: Progress, promise and challenges",
        "Dengue human infection models to advance dengue vaccine development",
        "Dengue human infection model: Re-establishing a tool for understanding dengue immunology and advancing vaccine development",
        "Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage",
        "A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates",
        "Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination",
        "Evaluation of pre-existing immunitity against dengue on neutralizing antibody response induced by a live attenuated tetravalent dengue vaccine, KD382, in Cynomolgus monkeys",
        "Single administration of live-attenuated tetravalent dengue vaccne candidate, KD-382, induced long-lasting (>2 years) neutralizing antibody against all four serotypes in Cynomolgus monkeys",
        "Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys",
        "A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity",
        "A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates",
        "Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity",
        "An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection",
        "Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses",
        "A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice",
        "Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells",
        "The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Syracuse",
            "@id": "60018741",
            "affilname": "SUNY Upstate Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018741",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Chulalongkorn Academic Advancement",
        "Special Task Force for Activating Research",
        "Chulalongkorn University"
    ]
}